TY - JOUR
T1 - Efficacy of electrical vestibular stimulation (VeNS) on adults with insomnia
T2 - A double-blind, randomized, sham-controlled trial
AU - Cheung, Teris
AU - Lam, Joyce Yuen Ting
AU - Fong, Kwan Hin
AU - Cheng, Calvin Pak Wing
AU - Xiang, Yu Tao
AU - Li, Tim Man Ho
N1 - Publisher Copyright:
© 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2025/7/11
Y1 - 2025/7/11
N2 - Introduction: Insomnia, a widespread sleep disorder, affects a significant portion of the global population. This study is the first in Asia to evaluate the efficacy of electrical vestibular stimulation (VeNS) as a treatment for insomnia in Hong Kong adults, addressing a gap in non-pharmacological interventions. Methods: A double-blind, randomized, sham-controlled trial was conducted with 101 adults exhibiting insomnia symptoms. Participants were randomized into active VeNS or sham groups (1:1 ratio) and underwent twenty 30-minute VeNS sessions over four weeks. Psychological outcomes, including insomnia severity, sleep quality, and quality of life were assessed at baseline (T1), post-intervention (T2). Follow-up assessments were conducted at one- (T3) and three-month (T4) to evaluate the sustainability of VeNS effects. Results: Of 83 participants (40 VeNS and 43 sham-VeNS), the VeNS group showed significant reductions in insomnia severity at T2 (p = 0.03, d = -0.47) and T4 (p = 0.02, d = -0.32), alongside improved quality of life (i.e., role-physical) at T2. Conclusion: VeNS is a novel, non-invasive and safe neuromodulation device that may serve as an adjunct treatment for primary insomnia. The present findings provide a foundation for future multisite comparison studies to further evaluate VeNS efficacy. Trial registration: ClinicalTrials.gov Identifier: NCT04452981.
AB - Introduction: Insomnia, a widespread sleep disorder, affects a significant portion of the global population. This study is the first in Asia to evaluate the efficacy of electrical vestibular stimulation (VeNS) as a treatment for insomnia in Hong Kong adults, addressing a gap in non-pharmacological interventions. Methods: A double-blind, randomized, sham-controlled trial was conducted with 101 adults exhibiting insomnia symptoms. Participants were randomized into active VeNS or sham groups (1:1 ratio) and underwent twenty 30-minute VeNS sessions over four weeks. Psychological outcomes, including insomnia severity, sleep quality, and quality of life were assessed at baseline (T1), post-intervention (T2). Follow-up assessments were conducted at one- (T3) and three-month (T4) to evaluate the sustainability of VeNS effects. Results: Of 83 participants (40 VeNS and 43 sham-VeNS), the VeNS group showed significant reductions in insomnia severity at T2 (p = 0.03, d = -0.47) and T4 (p = 0.02, d = -0.32), alongside improved quality of life (i.e., role-physical) at T2. Conclusion: VeNS is a novel, non-invasive and safe neuromodulation device that may serve as an adjunct treatment for primary insomnia. The present findings provide a foundation for future multisite comparison studies to further evaluate VeNS efficacy. Trial registration: ClinicalTrials.gov Identifier: NCT04452981.
KW - brain stimulation
KW - efficacy
KW - insomnia
KW - randomised clinical trial
KW - Vestibular stimulation
UR - https://www.scopus.com/pages/publications/105010510512
U2 - 10.1080/19585969.2025.2526547
DO - 10.1080/19585969.2025.2526547
M3 - Journal article
C2 - 40650353
AN - SCOPUS:105010510512
SN - 1294-8322
VL - 27
SP - 236
EP - 248
JO - Dialogues in Clinical Neuroscience
JF - Dialogues in Clinical Neuroscience
IS - 1
ER -